Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis: an observational cohort study
Naderi et al., Immunopathologia Persa, doi:10.34172/ipp.2021.29 (Preprint)
Naderi et al., Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis:.., Immunopathologia Persa, doi:10.34172/ipp.2021.29 (Preprint)
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective observational study of 215 RA patients treated with HCQ showing 9 cases, 1 hospitalization (without ICU/intubation), and no mortality.
Naderi et al., 31 Jan 2021, preprint, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/350855140 Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis: an observational cohort study Article in Immunopathologia Persa · April 2021 DOI: 10.34172/ipp.2021.29 CITATIONS READS 0 109 7 authors, including: Zohre Naderi Ziba Farajzadegan Isfahan University of Medical Sciences Isfahan University of Medical Sciences 13 PUBLICATIONS 164 CITATIONS 216 PUBLICATIONS 2,183 CITATIONS SEE PROFILE SEE PROFILE Ramin Sami Mansour Salesi Isfahan University of Medical Sciences Isfahan University of Medical Sciences 36 PUBLICATIONS 147 CITATIONS 54 PUBLICATIONS 648 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Frequency of positional obstructive sleep apnea (POSA) in patients with obstructive sleep apnea and differences in demographic and clinical characteristics View project Compliance with continuous positive airway pressure in Persian patients with obstructive sleep apnea View project All content following this page was uploaded by Zohre Naderi on 14 April 2021. The user has requested enhancement of the Original Immunopathol Persa. 2021;7(2):e29 http www.immunopathol.com Immunopathologia Persa DOI:10.34172/ipp.2021.29 Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis: an observational cohort study ID ID ID ID ID ID Zohre Naderi1 , Bahar Sadeghi2 , Ziba Farajzadegan3 , Ramin Sami1 , Mansour Salesi1* , Vahid Mansouri4* , ID Babak Amra5 Department of Internal Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Student Research Committee, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 3 Department of Community Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 4 Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 5 Bamdad Respiratory and Sleep Research Center, Pulmonary and Sleep Ward, Internal Medicine Department, Isfahan University of Medical Sciences, Isfahan, Iran 1 2 *Correspondence to Mansour Salesi, Email: Salesi@med.mui.ac.ir; Vahid Mansouri, Email: Mansoury.vahid@gmail. com Received 2 Jan 2021 Accepted 28 Feb. 2020 Published online 6 Apr. 2021 Keywords: COVID-19, Hydroxychloroquine, Prophylaxis, Rheumatic arthritis, Observational, Prospective Citation: Naderi Z, Sadeghi B, Farajzadegan Z, Sami R, Salesi M, Mansouri V, Amra B. Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis: an observational cohort study. Immunopathol Persa. 2021;7(2):e29. DOI:10.34172/ ipp.2021.29. Abstract Introduction: Rheumatoid arthritis (RA) is a systemic autoimmune disease with substantial morbidity and mortality. Anti-malarial drugs like hydroxychloroquine are indicated in several rheumatic diseases such as RA. Some reports have suggested hydroxychloroquine for prevention of COVID-19. Objectives: Whether hydroxychloroquine has prophylactic effects for COVID-19 in rheumatic patients. Patients and Methods: In this multicenter cohort-based observational study the preventive effect of hydroxychloroquine regarding the incidence and severity of COVID-19 was investigated in patients with RA who referred to..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit